NAGIOS: RODERIC FUNCIONANDO

Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran

Mostra el registre parcial de l'element

dc.contributor.author Curto Aguilera, Adrián es
dc.contributor.author Albaladejo Martínez, Alberto es
dc.contributor.author Alvarado Lorenzo, Alfonso es
dc.date.accessioned 2017-07-18T12:22:26Z
dc.date.available 2017-07-18T12:22:26Z
dc.date.issued 2017 es
dc.identifier.citation Curto Aguilera, Adrián ; Albaladejo Martínez, Alberto ; Alvarado Lorenzo, Alfonso. Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran. En: Journal of Clinical and Experimental Dentistry. 2017. Vol. 9, no. 2: 289 es
dc.identifier.uri http://hdl.handle.net/10550/59632
dc.description.abstract A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years. Patients being treated with oral anticoagulants are at higher risk for bleeding when undergoing dental treatments. A literature search was conducted through April 2016 for publications in the ISI Web of Knowledge, PubMed and Cochrane Library using the keywords “dabigatran”, “rivaroxaban”, “apixaban”, “edoxaban”, “new oral anticoagulants”, “novel oral anticoagulants”, “bleeding” and “dental treatment”. There is no need for regular coagulation monitoring of patients on dabigatran therapy. Whether or not to temporarily discontinue dabigatran must be assessed according to the bleeding risk involved in the dental procedure to be performed. The number of patients under treatment with new oral anticoagulants will increase in the coming years. It is essential to know about the pharmacokinetics and pharmacodynamics of new oral anticoagulants and about their interactions with other drugs. It is necessary to develop clinical guidelines for the perioperative and postoperative management of these new oral anticoagulants in oral surgical procedures, and to carefully evaluate the bleeding risk of dental treatment, as well as the thrombotic risk of suppressing the new oral anticoagulant. en_US
dc.subject Odontología es
dc.subject Ciencias de la salud es
dc.title Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.type.hasVersion VoR es_ES

Visualització       (418.1Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques